Nevirapine pharmacokinetics and risk of rash and hepatitis among HIV-infected sub-Saharan African women

AIDS

Volumn 26, Issue 7, 2012, Pages 833-841

  Dong, Betty J ^a   Zheng, Yu ^b   Hughes, Michael D ^b   Frymoyer, Adam ^c   Verotta, Davide ^d   Lizak, Patricia ^a   Sawe, Frederick ^e   Currier, Judith S ^f   Lockman, Shahin ^b,g   Aweeka, Francesca T ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d San Francisco   (United States)

^e KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

drug toxicity; hepatotoxicity; nevirapine; pharmacokinetics; rash

Indexed keywords

EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE;

ADULT; AFRICAN AMERICAN; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG WITHDRAWAL; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MAXIMUM PLASMA CONCENTRATION; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; TREATMENT WITHDRAWAL;

ADULT; AFRICA SOUTH OF THE SAHARA; CD4 LYMPHOCYTE COUNT; DRUG THERAPY, COMBINATION; DRUG-INDUCED LIVER INJURY; EXANTHEMA; FEMALE; HIV INFECTIONS; HUMANS; NEVIRAPINE; REVERSE TRANSCRIPTASE INHIBITORS; RISK FACTORS; TREATMENT OUTCOME;

EID: 84862815230     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328351a521     Document Type: Article

References (53)

1. WHO. Antiretroviral therapy for HIV infection in adults and adolescents. Recommendations for a public health approach: 2010 revision. 2010; 1-156. http://www.who.int/hiv/pub/arv/adult2010/en/index.html. [Accessed 20 August 2011].
2. Hahn JA, Maier M, Byakika-Tusiime J, Oyugi JH, Bangsberg DR. Hepatotoxicity during nevirapine-based fixed-dose combination antiretroviral therapy in kampala, Uganda. J Int Assoc Physicians AIDS Care (Chic) 2007; 6:83-86.
3. Martinez E, Blanco JL, Arnaiz JA, Perez-Cuevas JB, Mocroft A, Cruceta A, et al. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. AIDS 2001; 15:1261-1268. (Pubitemid 32592358)
4. Peters PJ, Stringer J, McConnell MS, Kiarie J, Ratanasuwan W, Intalapaporn P, et al. Nevirapine-associated hepatotoxicity was not predicted by CD4 count >-250 cells/muL among women in Zambia, Thailand and Kenya. HIV Med 2010; 11:650-660.
5. Sanne I, Mommeja-Marin H, Hinkle J, Bartlett JA, Lederman MM, Maartens G, et al. Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. J Infect Dis 2005; 191:825-829. (Pubitemid 40349795)
6. Aaron E, Kempf MC, Criniti S, Tedaldi E, Gracely E, Warriner A, et al. Adverse events in a cohort of HIV infected pregnant and nonpregnant women treated with nevirapine versus nonnevirapine antiretroviral medication. PLoS One 2010; 5:e12617.
7. Bersoff-Matcha SJ, Miller WC, Aberg JA, van Der Horst C, Hamrick HJ Jr, Powderly WG, Mundy LM. Sex differences in nevirapine rash. Clin Infect Dis 2001; 32:124-129. (Pubitemid 32150957)
8. De Requena DG, Jimenez-Nacher I, Soriano V. Changes in nevirapine plasma concentrations over time and its relationship with liver enzyme elevations. AIDS Res Hum Retroviruses 2005; 21:555-559. (Pubitemid 40944317)
9. Almond LM, Boffito M, Hoggard PG, Bonora S, Raiteri R, Reynolds HE, et al. The relationship between nevirapine plasma concentrations and abnormal liver function tests. AIDS Res Hum Retroviruses 2004; 20:716-722. (Pubitemid 39037502)
10. Hall DB, Macgregor TR. Case-control exploration of relationships between early rash or liver toxicity and plasma concentrations of nevirapine and primary metabolites. HIV Clin Trials 2007; 8:391-399. (Pubitemid 350305213)
11. de Maat MM, ter Heine R, Mulder JW, Meenhorst PL, Mairuhu AT, van Gorp EC, et al. Incidence and risk factors for nevirapine-associated rash. Eur J Clin Pharmacol 2003; 59:457-462. (Pubitemid 37214954)
12. Barreiro P, Soriano V, Casas E, Estrada V, Tellez MJ, Hoetelmans R, et al. Prevention of nevirapine-associated exanthema using slow dose escalation and/or corticosteroids. AIDS 2000; 14:2153-2157.
13. Kappelhoff BS, van Left F, Robinson PA, MacGregor TR, Baraldi E, Montella F, et al. Are adverse events of nevirapine and efavirenz related to plasma concentrations? Antivir Ther 2005; 10:489-498. (Pubitemid 41059195)
14. Schipani A, Wyen C, Mahungu T, Hendra H, Egan D, Siccardi M, et al. Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals. J Antimicrob Chemother 2011; 66:1332-1339.
15. Regazzi M, Villani P, Seminari E, Ravashi G, Cusato M, Marubbi F, et al. Sex differences in nevirapine disposition in HIVinfected patients. AIDS 2003; 17:2399-2400. (Pubitemid 38147029)
16. Gandhi M, Benet LZ, Bacchetti P, Kalinowski A, Anastos K, Wolfe AR, et al. Nonnucleoside reverse transcriptase inhibitor pharmacokinetics in a large unselected cohort of HIV-infected women. J Acquir Immune Defic Syndr 2009; 50:482-491.
17. de Maat MM, Huitema AD, Mulder JW, Meenhorst PL, van Gorp EC, Beijnen JH. Population pharmacokinetics of nevirapine in an unselected cohort of HIV-1-infected individuals. Br J Clin Pharmacol 2002; 54:378-385. (Pubitemid 35334950)
18. Von Hentig N, Carlebach A, Gute P, Knecht G, Klauke S, Rohrbacher M, et al. A comparison of the steady-state pharmacokinetics of nevirapine in men, nonpregnant women and women in late pregnancy. Br J Clin Pharmacol 2006; 62:552-559. (Pubitemid 44571576)
19. Lockman S, Hughes MD, McIntyre J, Zheng Y, Chipato T, Conradie F, et al. Antiretroviral therapies in women after single-dose nevirapine exposure. N Engl J Med 2010; 363:1499-1509.
20. Zhou XJ, Sheiner LB, D'Aquila RT, Hughes MD, Hirsch MS, Fischl MA, et al. Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infected patients. The National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators. Antimicrob Agents Chemother 1999; 43:121-128. (Pubitemid 29069210)
21. Taiwo BO. Nevirapine toxicity. Int J STD AIDS 2006; 17:364-369.
22. Wong KH, Chan KC, Lee SS. Sex differences in nevirapine rash. Clin Infect Dis 2001; 33:2096-2098.
23. de Maat MM, Nellen JF, Huitema AD, Wit FW, Mulder JW, Prins JM, Beijnen JH. Race is not associated with nevirapine pharmacokinetics. Ther Drug Monit 2004; 26:456-458. (Pubitemid 38989667)
24. Kappelhoff BS, Huitema AD, van Leth F, Robinson PA, MacGregor TR, Lange JM, et al. Pharmacokinetics of nevirapine: once-daily versus twice-daily dosing in the 2NN study. HIV Clin Trials 2005; 6:254-261. (Pubitemid 43025156)
25. Kappelhoff BS, van Leth F, MacGregor TR, Lange J, Beijnen JH, Huitema AD. Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study. Antivir Ther 2005; 10:145-155. (Pubitemid 40767640)
26. Molto J, Valle M, Miranda C, Cedeno S, Miranda J, Santos JR, et al. Once-or twice-daily dosing of nevirapine in HIV-infected adults: a population pharmacokinetics approach. J Antimicrob Chemother 2008; 62:784-792.
27. Sabo JP, Lamson MJ, Leitz G, Yong CL, MacGregor TR. Pharmacokinetics of nevirapine and lamivudine in patients with HIV-1 infection. AAPS Pharm Sci 2000; 2:1-8.
28. Van Heeswijk RP, Veldkamp AI, Mulder JW, Meenhorst PL, Wit FW, Lange JM, et al. The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals. AIDS 2000; 14:F77-F82. (Pubitemid 30336080)
29. Dailly E, Raffi F, Perre P, Martin J, Deslandes G, Jolliet P. Influence of darunavir coadministration on nevirapine pharmacokinetics in HIV-infected patients: a population approach. HIV Med 2009; 10:586-589.
30. Dailly E, Billaud E, Reliquet V, Breurec S, Perre P, Leautez S, et al. No relationship between high nevirapine plasma concentration and hepatotoxicity in HIV-1-infected patients naive of antiretroviral treatment or switched from protease inhibitors. Eur J Clin Pharmacol 2004; 60:343-348. (Pubitemid 39062320)
31. Stohr W, Back D, Dunn D, Sabin C, Winston A, Gilson R, et al. Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication. Antivir Ther 2008; 13:675-685.
32. Fletcher CV, Jiang H, Brundage RC, Acosta EP, Haubrich R, Katzenstein D, et al. Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group Study 359. J Infect Dis 2004; 189:1176-1184. (Pubitemid 38457241)
33. Umeh OC, Currier JS, Park JG, Cramer Y, Hermes AE, Fletcher CV. Sex differences in lopinavir and ritonavir pharmacokinetics among HIV-infected women and men. J Clin Pharmacol 2011; 51:1665-1673.
34. Gonzalez de Requena D, Nunez M, Jimenez-Nacher I, Soriano V. Liver toxicity caused by nevirapine. AIDS 2002; 16:290-291. (Pubitemid 34118577)
35. Crommentuyn KM, Huitema AD, Brinkman K, van der Ende ME, de Wolf F, Beijnen JH. Therapeutic drug monitoring of nevirapine reduces pharmacokinetic variability but does not affect toxicity or virologic success in the ATHENA study. J Acquir Immune Defic Syndr 2005; 39:249-250. (Pubitemid 40741125)
36. Van Leth F, Phanuphak P, Ruxrungtham K, Baraldi E, Miller S, Gazzard B, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. The Lancet 2004; 363:1253-1263. (Pubitemid 38496486)
37. Rotger M, Colombo S, Furrer H, Bleiber G, Buclin T, Lee BL, et al. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet Genomics 2005; 15:1-5. (Pubitemid 43205520)
38. Saitoh A, Sarles E, Capparelli E, Aweeka F, Kovacs A, Burchett SK, et al. CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children. AIDS 2007; 21:2191-2199. (Pubitemid 350287217)
39. Haas DW, Gebretsadik T, Mayo G, Menon UN, Acosta EP, Shintani A, et al. Associations between CYP2B6 polymorphisms and pharmacokinetics after a single dose of nevirapine or efavirenz in African americans. J Infect Dis 2009; 199:872-880.
40. Yuan J, Guo S, Hall D, Cammett AM, Jayadev S, Distel M, et al. Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent. AIDS 2011; 25:1271-1280.
41. Ciccacci C, Borgiani P, Ceffa S, Sirianni E, Marazzi MC, Altan AM, et al. Nevirapine-induced hepatotoxicity and pharmacogenetics: a retrospective study in a population from Mozambique. Pharmacogenomics 2010; 11:23-31.
42. Haas DW, Bartlett JA, Andersen JW, Sanne I, Wilkinson GR, Hinkle J, et al. Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration. Clin Infect Dis 2006; 43:783-786. (Pubitemid 44330746)
43. Baylor MS, Johann-Liang R. Hepatotoxicity associated with nevirapine use. J Acquir Immune Defic Syndr 2004; 35:538-539.
44. Dieterich DT, Robinson PA, Love J, Stern JO. Drug-induced liver injury associated with the use of nonnucleoside reversetranscriptase inhibitors. Clin Infect Dis 2004; 38 (Suppl 2):S80-S89. (Pubitemid 38328169)
45. Coffie PA, Tonwe-Gold B, Tanon AK, Amani-Bosse C, Bedikou G, Abrams EJ, et al. Incidence and risk factors of severe adverse events with nevirapine-based antiretroviral therapy in HIVinfected women. MTCT-Plus program, Abidjan, Cote d'Ivoire. BMC Infect Dis 2010; 10:1-10.
46. Nunez M. Hepatotoxicity of antiretrovirals: incidence, mechanisms and management. J Hepatol 2006; 44:S132-S139. (Pubitemid 43053889)
47. Ouyang DW, Brogly SB, Lu M, Shapiro DE, Hershow RC, French AL, et al. Lack of increased hepatotoxicity in HIVinfected pregnant women receiving nevirapine compared with other antiretrovirals. AIDS 2010; 24:109-114.
48. Antela A, Ocampo A, Gomez R, Lopez MJ, Marino A, Losada E, et al. Liver toxicity after switching or simplifying to nevirapinebased therapy is not related to CD4 cell counts: results of the TOSCANA study. HIV Clin Trials 2010; 11:11-17.
49. Knobel H, Guelar A, Montero M, Carmona A, Luque S, Berenguer N, et al. Risk of side effects associated with the use of nevirapine in treatment-naive patients, with respect to gender and CD4 cell count. HIV Med 2008; 9:14-18.
50. Hughes MD, Stein DS, Gundacker HM, Valentine FT, Phair JP, Volberding PA. Within-Subject variation in CD4 lymphocyte count in asymptomatic human immunodeficiency virus infection: implications for patient monitoring. J Infect Dis 1994; 169:28-36.
51. Malone JL, Simms TE, Gray GC, Wagner KF, Burge JR, Burke DS. Sources of variability in repeated T-helper lymphocyte counts from human immunodeficiency virus type 1-infected patients: total lymphocyte count fluctuations and diurnal cycle are important. J Acquir Immune Defic Syndr 1990; 3:144-151. (Pubitemid 20080777)
52. Raboud JM, Haley L, Montaner JS, Murphy C, Januszewska M, Schechter MT. Quantification of the variation due to laboratory and physiologic sources in CD4 lymphocyte counts of clinically stable HIV-infected individuals. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 10 (Suppl 2):S67-S73.
53. Williams BG, Korenromp EL, Gouws E, Schmid GP, Auvert B, Dye C. HIV infection, antiretroviral therapy, and CD4R cell count distributions in African populations. J Infect Dis 2006; 194:1450-1458. (Pubitemid 44706515)